Los Angeles--The largest clinical database built on renal cell carcinoma is beginning to yield definitive answers to questions about prognosis and treatment. Analyses of histories of more than 4,000 patients at eight academic medical centers worldwide has already indicated that tumor stage, grade, and performance status have a stronger influence on prognosis than tumor stage alone and that the indications for partial nephrectomy can expand.
Prostate cancer genomic tests show prognostic value for progression, therapy benefit
April 22nd 2024"This preplanned ENACT trial biomarker analysis demonstrates the value of the Decipher score, AR-A score, and PAM50 genomic classifiers in identifying patients undergoing AS who are most likely to benefit from enzalutamide treatment," wrote the authors.